Exploring Innovative Treatments: Appraising Novel Pharmacotherapies for Narcolepsy


Anne Marie Morse, DO, FAASM
Associate Professor
Geisinger Commonwealth School of Medicine
Director, Child Neurology and Pediatric Sleep Medicine, Geisinger Medical Center
Janet Weis Children’s Hospital
Danville, PA
Anne Marie Morse, DO, FAASM

Dr. Anne Marie Morse is the Director of Child Neurology and Pediatric Sleep Medicine at Geisinger, Janet Weis Children’s Hospital. She has significant clinical and research experience and interest in children, adolescents, and adults with sleep wake disorders, particularly central disorders of hypersomnolence. In addition, her research interests extend more broadly to include investigating the relationship between sleep and neurologic and neurodevelopmental disorders. Dr Morse’s commitment to sleep health extends into the community. She has developed a school-based sleep education and surveillance program called Wake Up and Learn.  This program was developed to provide education about sleep health and perform school-based sleep screening to improve recognition of pediatric sleep disorders in middle and high school students. It has now expanded to include learners in college, medical school, and medical residency programs with a clinical and health plan delivery, called Sleep to Be Well. Dr. Morse envisions a world where sleep can be acknowledged as the vital sign of health, wellness, and performance that it is designed to be.

Clete A. Kushida, MD, PhD
Neurologist, Division Chief, Medical Director, and Professor
Division of Stanford Sleep Medicine
Stanford University
Redwood City, CA

Statement of Need

Narcolepsy is a chronic sleep disorder that carries a high degree of disability and comorbidity. Patients often wait years for a proper diagnosis and treatment initiation, resulting in a tremendous negative impact to their quality of life. Pharmacotherapy for narcolepsy has historically been limited to traditional stimulants and twice-nightly GABA-B receptor agonist sodium oxybate. But recently, novel agents have been FDA approved, including solriamfetol, pitolisant, and once-nightly extended-release sodium oxybate, offering additional mechanisms and dosing regimens to positively impact patient care.

During this podcast, sleep experts will discuss the latest clinical trials on the safety and efficacy of currently available novel therapies for EDS and cataplexy in patients with narcolepsy as well as strategies to improve treatment adherence.

Learning Objectives

At the conclusion of this activity, learners will be able to better:

  • Evaluate the latest clinical trial data for novel pharmacotherapies for narcolepsy to differentiate among mechanisms and formulations

Financial Support

Supported by an educational grant from Avadel CNS Pharmaceuticals, LLC.

Target Audience

Sleep specialists, pulmonologists, psychiatrists, neurologists, primary care practitioners (PCPs), physician associates (PAs), nurse practitioners (NPs), nurses, and pharmacists

Credit Information

Jointly Accredited Provider

In support of improving patient care, CME Outfitters, LLC, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Interprofessional (IPCE) 0.75

This activity was planned by and for the healthcare team, and learners will receive 0.75 Interprofessional Continuing Education Credit for learning and change.

Physicians (ACCME) 0.75

CME Outfitters, LLC, designates this Enduring Material for a maximum of 0.75 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nurses (ANCC) 0.75

This activity is designated for 0.75 contact hours.

California Residents: This continuing nursing education activity was approved by the California Board of Registered Nursing. CME Outfitters LLC’s provider number is CEP15510.

Note to Nurse Practitioners: the content of this CNE activity pertains to Pharmacology.

Pharmacists (ACPE) 0.75

This application-based activity is approved for 0.75 contact hours ( 0.075 CEUs) of continuing pharmacy credit ( JA0007185-0000-24-016-H01-P ).

PAs (AAPA) 0.75

CME Outfitters, LLC, has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 0.75 AAPA Category 1 CME credits. Approval is valid until 02/26/25. PAs should only claim credit commensurate with the extent of their participation.


Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.75 medical knowledge MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

MIPS Improvement Activity

Completion of this accredited CME activity meets the expectations of an Accredited Safety or Quality Improvement Program (IA_PSPA_28) for the Merit-based Incentive Payment Program (MIPS). Clinicians should submit their improvement activities by attestation via the CMS Quality Payment Program website.

Royal College MOC

Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME’s “CME in Support of MOC” program in Section 3 of the Royal College’s MOC Program.

Disclosure Declaration

Dr. Morse reports the following financial relationships:

Advisory Board: Alkermes; Avadel Pharmaceuticals; Harmony Biosciences; Jazz Pharmaceuticals, Inc.; and Takeda Pharmaceuticals U.S.A., Inc.

Grants: Coverys Community Healthcare Foundation; Jazz Pharmaceuticals, Inc.; and ResMed Foundation

Research Support: Geisinger Health Plan; Jazz Pharmaceuticals, Inc.; and UCB, Inc.

Speakers Bureau: Jazz Pharmaceuticals, Inc.

Employment: DAMM Good Sleep, LLC (CEO)

Dr. Kushida reports the following financial relationships:

Advisory Board: Avadel Pharmaceuticals; Cerebra Heath Inc.; and Samsung

Consultant: Asleep Inc.; Eisai Inc.; Genentech, Inc.; Koko Home, Inc.; Morgan Stanley; Oxama Medical; Restful Robotics Inc.; Sound Health Inc.; and Vivos Therapeutics, Inc.

Research Support: Avadel Pharmaceuticals; and Eisai Inc.

The following individuals have no financial relationships to disclose: 

Rebecca Vargas-Jackson, MD (Peer Reviewer)
Shirley Michelle Franks, MSN, APRN, FNP-BC (Peer Reviewer)
Thomas Mitchell (Planning Committee)
Erin Spencer, PharmD (Planning Committee)
Susan H. Yarbrough, CHCP (Planning Committee)
Sandra Caballero, PharmD (Planning Committee)
Sharon Tordoff (Planning Committee)

Obtaining Credit

Post-tests, credit request forms, and activity evaluations must be completed online (requires free account activation), and participants can print their certificate or statement of credit immediately (70% pass rate required). This website supports all browsers except Internet Explorer for Mac.

Questions about this activity?

Call us at 877.CME.PROS (877.263.7767).


Exploring Innovative Treatments: Appraising Novel Pharmacotherapies for Narcolepsy
Event Date: 02/26/2024 at 5:00 am EST